Entrectinib cost per month

Entrectinib (Entrectinib), as an oral small molecule targeted drug targeting ROS1 and NTRK gene fusion, has played an important role in the precision treatment ofnon-small cell lung cancer and a variety of rare solid tumors. With the improvement of the domestic precision medicine and targeted therapy system, entrectinib has been launched in China and has been included in the national medical insurance directory, which has greatly improved the accessibility of the drug and made patients pay more attention to its cost. Clinically, the usual dose for adults is 600 mg orally per day, which is continued until disease progression or intolerable toxicity occurs. In this context, patients are particularly sensitive to the monthly cost of entrectinib.

Currently, entrectinib on the domestic market is mainly available in 100mg and 200mg specifications. Common packaging includes 30 tablets of 100mg and 90 tablets of 200mg. If taken according to the recommended dosage, one month's treatment costs about 20,000 yuan. Thanks to medical insurance reimbursement, the actual costs borne by patients are significantly reduced. Depending on the differences in medical insurance reimbursement ratios in different regions, the personal burden may be only a part of the original price. This kind of policy support not only reduces financial pressure on patients, but also promotes the popularization of the drug in clinical practice.

In addition to domestic channels for original drugs, some patients will also pay attention to the price situation in overseas markets. In countries such as Laos and India, generic versions of entrectinib have been approved for production. Its ingredients are consistent with the original drug. The specifications are 100mg*60 capsules, and the price per box is more than 1,000 yuan. The average monthly cost is much lower than that of the domestic original drug. Affected by exchange rate changes, logistics costs and policy differences, overseas drug prices fluctuate to a certain extent, but overall they are still lower than the domestic market. However, patients need to pay attention to the quality and source of drugs when choosing, especially under the guidance of a doctor to ensure drug efficacy and safety.

Reference materials:https://www.roche.com/products/rozlytrek